Calcitonin gene-related peptide: an update on the biology
- 1 June 2009
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 22 (3) , 241-246
Abstract
Purpose of review This review includes the most relevant and recent studies on the biology of calcitonin gene-related peptide (CGRP) as it pertains to primary headaches and particularly to migraine. Especial attention was given to those published within the last year. Recent findings The development of CGRP receptor antagonists is discussed in detail, as well as recent advances in our understanding of CGRP actions in migraine. Finally, other important functions of CGRP outside of the nervous system are briefly discussed. Summary The advent of CGRP receptor antagonists as a novel therapy for migraine attacks may represent a new era in the acute management of migraine. More than a simple addition to the currently available treatments, this group of drugs may become an outstanding option for patients with cardiovascular disease, given the lack of associated vasoconstriction. Furthermore, nonpeptide CGRP receptor antagonists, CGRP antibodies and CGRP-binding RNA-Spiegelmer are valuable research tools that will further advance our understanding of migraine pathophysiology.Keywords
This publication has 62 references indexed in Scilit:
- Calcitonin Gene-Related Peptide Receptor Inhibition Reduces Neuronal Activity Induced by Prolonged Increase in Nitric Oxide in the Rat Spinal Trigeminal NucleusCephalalgia, 2009
- Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trialThe Lancet, 2008
- CGRP blockers in migraine therapy: where do they act?British Journal of Pharmacology, 2008
- Crystal structure of the human receptor activity‐modifying protein 1 extracellular domainProtein Science, 2008
- Clinical and Preclinical Rationale for CGRP‐Receptor Antagonists in the Treatment of MigraineHeadache: The Journal of Head and Face Pain, 2008
- Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraineNeurology, 2008
- Technology Insight: therapeutic RNA interference—how far from the neurology clinic?Nature Clinical Practice Neurology, 2007
- Determinants of 1-Piperidinecarboxamide, N-[2-[[5-Amino-l-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl) (BIBN4096BS) Affinity for Calcitonin Gene-Related Peptide and Amylin Receptors—The Role of Receptor Activity Modifying Protein 1Molecular Pharmacology, 2006
- Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of MigraineNew England Journal of Medicine, 2004
- Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonistBritish Journal of Pharmacology, 2000